Frailty may increase risk of adverse outcomes in RA patients on biologic or targeted-synthetic DMARDs
USA: A recent study published in Arthritis Care & Research has shown frailty to be an important predictor for the risk of serious infections among rheumatoid arthritis (RA) patients treated with biologic (b) or targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs). Disease-modifying antirheumatic drugs are a group of medications commonly used in rheumatoid arthritis patients. Some […]